Sun Pharma Advanced Research Company Ltd - 532872 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to regulation 39(3) of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we hereby inform you that, the Company has issued duplicate share certificates as per attached details. We request you to kindly take the same on record. SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Update On TACLANTIS(tm) (Paclitaxel Injection Concentrate For Suspension) NDA
Dear Sir/Madam, Pursuant to regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we inform you that Office of New Drugs (OND) of the U.S. Food and Drug Administration (FDA) has denied the Company's appeal of the Complete Response Letter in relation to the New Drug Application (NDA) for Taclantis(tm). In its Appeal Denied letter, the OND requested the conduct of a new Phase 3 study in metastatic breast cancer patients to support any potential resubmission of the Taclantis(tm) NDA. The Company will review FDA's response and decide on appropriate next steps soon. SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Update On TACLANTIS(tm) (Paclitaxel Injection Concentrate For Suspension) NDA
Dear Sir/Madam, Pursuant to regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we inform you that Office of New Drugs (OND) of the U.S. Food and Drug Administration (FDA) has denied the Company's appeal of the Complete Response Letter in relation to the New Drug Application (NDA) for Taclantis(tm). In its Appeal Denied letter, the OND requested the conduct of a new Phase 3 study in metastatic breast cancer patients to support any potential resubmission of the Taclantis(tm) NDA. The Company will review FDA's response and decide on appropriate next steps soon. SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 20, 2021 for Raksha Sudhir Valia SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Outcome Of Board Meeting Held On 8Th February 2021.
The Board of Directors of the Company at their meeting held from 07:00 pm to 09:15 pm today, inter alia, took on record and duly approved the Un-audited financial results of the Company for the quarter ended 31st December 2020 which is enclosed herewith along with the Limited Review Report of the Auditors thereon as Annexure I. SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Outcome Of Board Meeting Held On 8Th February 2021.
The Board of Directors of the Company at their meeting held from 07:00 pm to 09:15 pm today, inter alia, took on record and duly approved the Un-audited financial results of the Company for the quarter ended 31st December 2020 which is enclosed herewith along with the Limited Review Report of the Auditors thereon as Annexure I. SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Board Meeting Intimation for Notice Of Board Meeting For Consideration Of Unaudited Financial Results Of The Company For The Quarter Ended 31St December 2020.
SUN PHARMA ADVANCED RESEARCH COMPANY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2021 ,inter alia, to consider and approve Pursuant to regulation 29 (1) of the SEBI (Listing obligation & Disclosure Requirements) Regulation, 2015, we hereby inform you that a meeting of the Board of Directors of Sun Pharma Advanced Research Company Limited will be held on Monday, 8th February 2021, inter alia, to consider and take on record, the unaudited financial results of the Company for the quarter ended 31st December 2020. Further, kindly note that pursuant to the Company's Code of Conduct for Prevention of Insider Trading, the trading window for trading by designated persons, shall remain closed upto 48 hours after the declaration of financial results of the Company on 8th February 2021. SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on January 28, 2021 for Raksha Sudhir Valia Two stocks that Vaishali Parekh of Prabhudas Lilladher is bullish on
The chart looks attractive for further upside movement in SPARC with the RSI indicator also showing a trend reversal SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Shareholding for the Period Ended December 31, 2020
Sun Pharma Advanced Research Company Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2020. For more details, kindly Click here